טוען...
Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...
שמור ב:
| הוצא לאור ב: | BMC Med |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/ https://ncbi.nlm.nih.gov/pubmed/26137986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|